Sydney, Australia — Human Health, an emerging Australian health technology startup founded by former Canva executives, has secured an $8.4 million partnership to accelerate the development of RhinoMAP, an artificial intelligence–driven biomarker platform designed to transform the management of chronic respiratory conditions.

Addressing a Persistent Clinical Challenge

Chronic respiratory diseases such as asthma and chronic rhinosinusitis are often treated with advanced biologic therapies. While these treatments can be highly effective, clinical studies show that nearly half of patients fail to respond adequately, leading to wasted healthcare resources, delayed recovery, and increased patient frustration.

RhinoMAP aims to tackle this challenge by combining nasal biomarker analysis with patient-reported data inputs to generate individualized disease profiles. By identifying biomarkers that correlate with treatment responsiveness, the platform seeks to reduce ineffective biologic therapy use from the current rate of around 50 percent to just 10 percent.

The Role of AI in Precision Care

The platform leverages machine learning models to analyze complex datasets of nasal fluid biomarkers alongside clinical symptoms, demographics, and treatment history. The result is a precision-medicine tool that can guide physicians in tailoring therapy decisions to each patient’s unique biological and clinical profile.

“Respiratory illnesses are notoriously heterogeneous,” Human Health’s leadership explained. “Two patients with the same diagnosis may respond completely differently to the same treatment. Our mission with RhinoMAP is to give clinicians a smarter way to match the right treatment to the right patient at the right time.”

Industry Collaboration and Funding

The $8.4 million partnership—backed by healthcare investors and strategic research collaborations—underscores growing recognition of AI’s potential in personalized medicine. Human Health intends to work closely with clinical specialists, diagnostic labs, and pharmaceutical partners to validate RhinoMAP in real-world settings before scaling the platform for widespread adoption.

A Broader Vision for Respiratory Care

Beyond treatment optimization, RhinoMAP is envisioned as a continuous monitoring tool, enabling ongoing assessment of disease progression and therapy effectiveness. Patients could track symptoms and receive tailored feedback, while clinicians gain longitudinal insights to refine treatment strategies.

If successful, the platform could serve as a model for applying biomarker-driven AI in other chronic disease areas where treatment response varies widely, including autoimmune disorders and oncology.

The Future of AI in Healthcare

The rise of startups like Human Health reflects a shift toward AI-enabled precision medicine. By focusing on biomarker intelligence, the company seeks not only to improve outcomes for patients but also to reduce unnecessary healthcare expenditures and make advanced therapies more sustainable for health systems.

With RhinoMAP, Human Health is positioning itself at the intersection of digital innovation, clinical science, and patient empowerment—an approach that could help reshape the future of respiratory care.